News Sentiment

CING sentiment intelligence

Cingulate Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.91 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.7% over one week, +0.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -8.7% Price reacting lower
Trend fit Trend inactive 0.6% over four weeks
Fair value -79.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 9
TradingView 8
GlobeNewswire 2
TradingKey 2
Investing.com 2
TMX Newsfile 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 15
Regulatory and legal 2
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Minichart Direct company coverage

Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information

Cingulate Inc. announced key outcomes from its 2026 Annual Meeting, including the approval of an amendment to its 2021 Omnibus Equity Incentive Plan to increase authorized shares by 625,000, bringing the total to 2,221,126. Shareholders also ratified KPMG LLP as the independent a

Tone
Positive 63/100
Event
Regulatory and legal
Published
14 Jul 2026 15:06
Source
Minichart
Quartr Direct company coverage

Cingulate (CING) Proxy filing Summary

Cingulate Inc. (CING) has released a proxy filing summary detailing the key proposals for its Annual Meeting scheduled for July 9, 2026. Shareholders will vote on the election of Jeff Hargroves as a Class II director, the ratification of KPMG LLP as the independent auditor, and a

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:11
Source
Quartr
TradingView Direct company coverage

Enterprise value to revenue forward of Cingulate Inc. – NASDAQ:CING

This article briefly mentions the enterprise value to revenue forward for Cingulate Inc. (NASDAQ: CING). It appears to be an excerpt from a financial data platform, likely TradingView, providing financial oversight for the company. The content focuses on the stock's financial met

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 09:12
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cingulate Inc. – NASDAQ:CING

This article displays the "Price to sales forward" metric for Cingulate Inc. (NASDAQ: CING). The content is primarily a data placeholder within a financial platform, showing the company's ticker, market, and a period value for this specific financial ratio. No detailed analysis o

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cingulate Inc. – NASDAQ:CING

The article provides a financial data point for Cingulate Inc. (NASDAQ: CING), specifically mentioning its "Price to book forward." It indicates the company's market and financial status, noting that the market was closed with no trades at the time of publication. The content als

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 00:40
Source
TradingView
GlobeNewswire Direct company coverage

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Cingulate Inc. announced its inclusion in the Russell 3000E® Index, a significant achievement expected to enhance visibility among institutional investors and market awareness. CEO Shane Schaffer stated this inclusion reinforces the company's commitment to long-term growth as it

Tone
Positive 92/100
Event
Market update
Published
03 Jul 2026 12:09
Source
GlobeNewswire
Investing.com UK Direct company coverage

Form 4 Cingulate Inc For: 2 July By Investing.com

This article reports on a Form 4 filing for Cingulate Inc. on July 2. It is a brief announcement from Investing.com and provides no further details beyond the filing date. The surrounding content consists of various market data, news headlines, and navigational elements typical o

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:13
Source
Investing.com UK
Stock Titan Direct company coverage

Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options

Cingulate Inc.'s EVP and CSO, Raul R. Silva, was granted 3,885 stock options at an exercise price of $5.47 per share, as reported in a recent Form 4 filing. These options, which expire in 2036, are part of his compensation agreement and do not represent a market purchase or sale

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E

Cingulate Inc. (NASDAQ: CING) announced its inclusion in the Russell 3000E Index, a significant milestone expected to boost its visibility among institutional investors. Concurrently, the biopharmaceutical company extended its Chief Medical Officer Matthew N. Brams' employment tr

Tone
Positive 66/100
Event
Market update
Published
02 Jul 2026 13:09
Source
Stock Titan
TradingView Direct company coverage

Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings

This article provides access to Cingulate Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports and corporate presentations, ranging from 2022 to the first quarter of 2026. Key disclosures highlight the company's progress with its CTX-1

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 07:41
Source
TradingView
www.marketscreener.com Direct company coverage

Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index

Cingulate Inc. (NasdaqCM: CING) has been added to the Russell Microcap Growth Benchmark Index, a significant development for the biopharmaceutical company. This inclusion reflects the company's growth trajectory and its focus on developing innovative therapies for conditions like

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 12:41
Source
www.marketscreener.com
TradingView Direct company coverage

CING Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Cingulate Inc. (CING) stock, based on analyst opinions. It details the company's current stock price, recent performance, market capitalization, and upcoming earnings report. The piece also addresses frequently asked questions

Tone
Positive 60/100
Event
Analyst action
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Cingulate, Inc. Actuals & Estimates (NASDAQ:CING)

This article provides an overview of Cingulate Inc. (NASDAQ: CING) stock, presenting its current price, historical performance, analysts' forecasts, and volatility. It also details the company's financial data, including market capitalization, recent earnings, revenue, and future

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:11
Source
TradingView
TradingKey Direct company coverage

Cingulate Inc (CINGW) Institutional Confidence

This article focuses on the institutional confidence in Cingulate Inc (CINGW), detailing changes in institutional shareholding. It lists several institutional investors and their holdings, noting significant decreases from firms like Citadel Advisors LLC and Armistice Capital LLC

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cingulate Inc (CING) stock performance and its history of dividends and stock splits. CING has not distributed any dividends over the past five years. However, the company has undergone multiple merger-related stock splits, including 12-for-1

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:39
Source
TradingKey
markets.businessinsider.com Direct company coverage

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Cingulate Inc. announced the issuance of its first U.S. patent for CTx-1301, its lead ADHD asset, covering the formulation and method of use through December 2042. This patent strengthens the company's intellectual property portfolio for its Precision Timed Release™ (PTR™) drug d

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 20:11
Source
markets.businessinsider.com
TradingView Direct company coverage

Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042

Cingulate has been granted a U.S. patent for CTx-1301, its lead ADHD asset, extending its protection through December 2042. This patent covers the formulation and method of use for its trimodal Precision Timed Release tablet technology. This marks the company's first owned U.S. p

Tone
Positive 75/100
Event
Market update
Published
16 Jun 2026 12:09
Source
TradingView
Stock Titan Direct company coverage

US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity

Cingulate Inc. announced the issuance of a new U.S. Patent No. 12,653,791 for its lead ADHD therapeutic candidate, CTx-1301, protecting its formulation and method of use through December 2042. This patent strengthens Cingulate's intellectual property for its Precision Timed Relea

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

New once-daily ADHD pill design gets U.S. patent, protecting Cingulate’s CTx-1301 to 2042

Cingulate Inc. has received its first U.S. patent for its lead ADHD drug candidate, CTx-1301, extending protection for its unique "Trimodal, Precision-Timed Pulsatile Release Tablet" until December 2042. This patent covers composition-of-matter, formulation, structural, and metho

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 12:09
Source
Stock Titan
Investing.com Direct company coverage

Cingulate director Hargroves buys $490,271 of common stock

Cingulate Inc. director Thomas Jeffrey Hargroves, through Hargroves Family Investments, LLC, purchased 97,276 shares of common stock for $490,271 and 77,821 warrants in February 2026. Hargroves also received 15,000 stock options in March 2026. These transactions, part of a privat

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 13:40
Source
Investing.com
TMX Newsfile Direct company coverage

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Stonegate Capital Partners updated its coverage on Cingulate Inc. after the FDA issued a Complete Response Letter for CTx-1301 due to CMC information requests, not clinical safety/efficacy issues. The firm believes the delay is a timing issue rather than a product viability conce

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 21:10
Source
TMX Newsfile
Stock Titan Direct company coverage

FDA focuses on manufacturing for Cingulate CTx-1301, not safety

Stonegate Capital Partners updated its coverage on Cingulate (NASDAQ:CING) after the FDA issued a Complete Response Letter (CRL) for CTx-1301, focusing solely on manufacturing information requests rather than clinical safety or efficacy concerns. Cingulate management believes its

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 21:10
Source
Stock Titan
AJMC Direct company coverage

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

The FDA issued a Complete Response Letter (CRL) for Cingulate Inc.'s New Drug Application (NDA) for CTx-1301, an investigational ADHD treatment. The CRL focused solely on Chemistry, Manufacturing, and Controls (CMC) documentation and did not raise concerns about the drug's clinic

Tone
Negative 37/100
Event
Regulatory and legal
Published
03 Jun 2026 15:08
Source
AJMC